الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>NI-42

NI-42

رقم الكتالوجGC36734

NI-42 (مركب 13-د) ، مسبار كيميائي متعامد هيكليًا لـ BRPFs ، هو مثبط قوي متحيز لـ BRD لـ BRPFs (IC50s من BRPF1 / 2/3 = 7.9 / 48/260 نانومتر ؛ Kds من BRPF1 / 2/3 = 40/210/940 نانومتر) مع انتقائية ممتازة على بروتينات BRD غير من الفئة IV

Products are for research use only. Not for human use. We do not sell to patients.

NI-42 التركيب الكيميائي

Cas No.: 1884640-99-6

الحجم السعر المخزون الكميّة
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NI-42 (compound 13-d), a structurally orthogonal chemical probe for the BRPFs, is a biased, potent inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM) with excellent selectivity over nonclass IV BRD proteins[1]. BRPF1|7.9 nM (IC50)|BRPF2|48 nM (IC50)|BRPF3|260 nM (IC50)|BRPF1|40 nM (Kd)|BRPF2|210 nM (Kd)|BRPF3|940 nM (Kd)|BRD4 (BD1)|4500 nM (IC50)|BRD7|82 nM (IC50)|BRD9|310 nM (IC50)|BRD9|1130 nM (Kd)

NI-42 shows IC50s of 82, 310, and 4500 nM for BRD7, BRD9, and BRD4 (BD1), respectively, and has a Kd of 1130 nM for BRD9[1].

[1]. Igoe N, et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. J Med Chem. 2017 Jan 26;60(2):668-680.

مراجعات

Review for NI-42

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NI-42

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.